Please login to the form below

heart failure

This page shows the latest heart failure news and features for those working in and with pharma, biotech and healthcare.

Pfizer finalises $6.7bn acquisition of Arena Pharmaceuticals

Arena brings with it two development-stage cardiovascular assets – temanogrel for Raynaud's phenomenon secondary to systemic sclerosis and microvascular obstruction, and APD418 for acute heart failure.

Latest news

Pfizer buys Arena in $6.7bn deal to broaden immuno-inflammatory portfolio

Temanogrel is in phase 2 for the treatment of microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis, while APD418 is in phase 2 for acute heart failure.
AstraZeneca and Ionis sign $3.6bn deal for eplontersen

ATTR-CM is a systemic, progressive and fatal condition that leads to heart failure and death within four years from diagnosis that remains under-diagnosed due to a lack of disease
AstraZeneca/Moderna’s mRNA treatment for heart failure looks promising

The trial met its primary endpoint of safety and tolerability in patients with heart failure and ‘a positive trend’ in clinical endpoints. ... Heart failure, which affects more than 60 million people worldwide, is a chronic disease where half of
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

The increase was driven by the strong performance of its heart failure combination Entresto (sacubitril/valsartan) which was up by 44%, psoriasis antibody Cosentyx (secukinumab) up by 22%, myelofibrosis drug Jakavi
Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

the composite primary endpoint of cardiovascular death or hospitalisation for heart failure in adults with heart failure with preserved ejection fraction. ... Empagliflozin also reduced the relative risk of first and recurrent hospitalisations for heart

More from news
Approximately 49 fully matching, plus 265 partially matching documents found.

Latest Intelligence

My journey advancing the science in pulmonary hypertension

By Neil Davie. I have worked in pulmonary hypertension (PH) – a serious, progressive disease that can lead to heart failure and early death – for many years now, but it all began ... At the time the only realistic treatment option for her was a heart
Mapping patient pathways with a focus on patient-centricity: the role of medical education

She has a point. Patients should always be at the heart of everything we do in medical education. ... Currently, we are developing MDT education in oncology, heart failure, diabetes, HIV and asthma.
How early-stage clinical research is facilitating the new wave of personalised medicines

We saw the demands of this last year during a first-in-human study focused on a therapy with the potential to halt and reverse heart failure by blocking crucial regulatory ... RNA. This successful phase 1b study in collaboration with Cardior
Understand, identify and partner with HCPs to improve patient support

patients are at risk of heart failure or stroke.
AI and accelerated computing ring in new era for healthcare

The typical drug discovery process takes about a decade, costs $2bn and suffers a 90% failure rate during clinical development. ... The project is initially connecting four of London’s premier teaching hospitals, offering AI services to accelerate work

More from intelligence
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest appointments

uniQure appoints chief executive officer

for congestive heart failure and Huntington's disease into the clinic.”.
Cardio3 BioSciences appoints Warren Sherman chief medical officer

Sherman has over 30 years' cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.
Acorda appoints new CFO

pain and heart failure.
Cardioxyl appoints Novartis scientist as chief medical officer

Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at ... Her unique combination of both early- and late-stage
CytomX makes senior changes following Pfizer deal

Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he worked in the development of products in nephrology, diabetes and heart failure.

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

Cardiovascular disease: The scale of the challenge

As part of efforts set out in NHS England’s Long Term Plan to prevent 150, 000 deaths over the next decade from the likes of heart attacks and strokes, the ... Thousands of cases of stroke, diabetes, heart failure and kidney disease could and should be
Claire wins Healthcare Communications Leader at Communiqué 2021

Excellence in Patient Programmes for our work with Novartis.The Fighting Failure: Reprioritising Heart Failure Care in the UK campaign created practical resources for the heart failure (HF) community and a
Communiqué 2021 – in real life!

Fighting Failure: Reprioritising Heart Failure Care in the UK with Novartis is a finalist in Excellence in Patient Programmes.The campaign created practical resources for the heart failure (HF) community and
Remote Patient Monitoring

3. It can be especially helpful for patients who are managing a more complex self-care processes such as post-operative care, home dialysis, diabetes or congestive heart failure.
Nanobiotechnology, Artificial Intelligence, and Virtual Care

Venk Varadan, Co-founder &CEO at Nanowear, explores the use of cloth-based nanosensor technology, AI, and deep-learning-enabled diagnostics for remote monitoring of congestive heart failure, chronic diseases, and